Personalized Chemotherapy for Advanced Hodgkin Lymphoma
This study is testing a personalized approach to treating advanced Hodgkin lymphoma (a type of cancer that starts in white blood cells called lymphocytes). It uses chemotherapy drugs like nivolumab, doxorubicin, vinblastine, and dacarbazine. The goal is to see if we can reduce the amount of chemotherapy you receive based on a blood test that looks for circulating tumor DNA (ctDNA). This DNA is released into your bloodstream by cancer cells. If your ctDNA levels are undetectable after two cycles of treatment, you may receive less chemotherapy overall. The study aims to see how long patients live without their cancer growing or coming back after one year. You may be able to join if you are 18 or older, have advanced Hodgkin lymphoma that hasn't been treated with systemic therapy before, and meet other health requirements. The current recruitment status is unclear.
- Study design
- This is a Phase II interventional study planning to enroll 125 participants. It is designed to personalize treatment based on individual patient response.
- What's involved
- You will undergo blood sample collections, CT scans, and echocardiography tests. You will receive chemotherapy treatments over several cycles, with follow-up appointments for up to 5 years.
- Compensation
- Not stated in the trial record.
- Follow-up
- After treatment, you will be followed up every 3 months for 1 year, then periodically for up to 5 years.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
NCT06745076
Personalized Reduction of Chemotherapy Intensity Through ctDNA Evaluation for the Treatment of Patients With Advanced Hodgkin Lymphoma
Recruiting
PHASE2Ages 18+InterventionalTreatmentUniversity of WashingtonInvestigator-initiated
~125 participants
Updated 2026-08-20 on ClinicalTrials.gov
What's tested:Biospecimen CollectionComputed TomographyDacarbazineDoxorubicinEchocardiography TestMultigated Acquisition Scan
At a glance
Recruiting sites
6 of 6 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Progression free survival (PFS) in patients with undetectable minimal residual disease (MRD) after 2 cycles of treatment
Measured over At 1 year
Conditions
Where it's being run
6 sites across 5 statesCalifornia2
Massachusetts1
Missouri1
New York1
Washington1
Study leadership
- Ryan Lynch, MD · PRINCIPAL_INVESTIGATOR · Fred Hutch/University of Washington Cancer Consortium
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Classical Hodgkin lymphoma without prior systemic therapy, stage 3 or 4. Corticosteroids for symptom relief are allowed
Measurable disease per Lugano criteria
Patients must be appropriate candidates for 6 cycles of combination chemotherapy including an anthracycline
No evidence of active central nervous system lymphoma
Eastern Cooperative Oncology Group (ECOG) performance status 0-2
Absolute neutrophil count (ANC) ≥ 500/mm\^3. Growth factor and/or transfusion support is permissible to stabilize participant prior to study treatment if needed. There is no lower limit to cytopenias if related to bone marrow involvement or underlying Hodgkin lymphoma
Platelets ≥ 50,000/mm\^3 (without transfusion or growth factor support). Growth factor and/or transfusion support is permissible to stabilize participant prior to study treatment if needed. There is no lower limit to cytopenias if related to bone marrow involvement or underlying Hodgkin lymphoma
Hemoglobin ≥ 8 g/dL. Growth factor and/or transfusion support is permissible to stabilize participant prior to study treatment if needed. There is no lower limit to cytopenias if related to bone marrow involvement or underlying Hodgkin lymphoma
Serum creatinine \< 1.5 x upper limits of normal (ULN) or creatinine clearance greater than 30/ml per minute by Cockcroft Gault formula
Total bilirubin ≤ 1.5 times upper limit of normal OR direct bilirubin ≤ ULN for participants with total bilirubin levels \> 1.5 × ULN). Patients with Gilbert Syndrome and direct bilirubin \< 1.5 x ULN or confirmatory UGT1A1 testing are allowed to enroll
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 times upper limit of normal (≤ 5 × ULN for participants with liver involvement)
Patients must be age 18 or older
All patients must be informed of the investigational nature of this study and have given written consent in accordance with institutional and federal guidelines
Patients must be anticipated to complete all planned study therapy
Male patients must agree to use an adequate method of barrier contraception starting with the first dose of study therapy through 120 days after the last dose of study therapy
Female patients of childbearing potential must have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Female patients of childbearing potential must be willing to use 2 methods of birth control or be surgically sterile or abstain from heterosexual activity for the course of the study through 120 days after the last dose of study medication. Subjects of childbearing potential are those who have not been surgically sterilized or have not been free from menses for \> 1 year
Exclusion
Patients known positive for HIV or infectious hepatitis type B or C with a detectable viral load may not participate. Hepatitis B/C, and HIV testing are not required at screening unless mandated by local health authority.
Patients living with HIV, on anti-viral treatment and undetectable viral load are allowed
Patients with positive hepatitis (hep) B core antibody are allowed on study with an undetectable viral load and appropriate prophylaxis
Patients with positive hepatitis C antibody are allowed with undetectable viral load
Pregnant or nursing women. Men or women of reproductive potential may not participate unless they have agreed to use an effective contraceptive method
Patients with other prior malignancies except for adequately treated basal cell carcinoma, squamous cell carcinoma of the skin, breast or cervical cancer in situ, or other cancer from which the patient has been disease-free for 2 years or greater, unless approved by the principal investigator
Patients who have other medical conditions that would contraindicate treatment with aggressive chemotherapy (including active infection, uncontrolled hypertension, congestive heart failure, unstable angina pectoris, or myocardial infarction within the past 6 months, uncontrolled arrhythmia, severe pulmonary disease or requirement of supplemental oxygen)
Active ischemic heart disease (eg. myocardial infarction within 6 months) or congestive heart failure (eg. left ventricular ejection fraction \< 50%)
Concurrent use of other anti-cancer agents or experimental treatments
Known current or prior autoimmune disease with the exception of vitiligo. Patients with a history of autoimmune thyroid disease on a stable dose of thyroid hormone are also allowed
Active or prior history of pneumonitis/interstitial lung disease that required corticosteroids
Current use of supplemental oxygen
Is known to have received a live vaccine or live-attenuated vaccine within 30 days prior to the first dose of trial treatment. Other non-live or live-attenuated vaccines (eg. COVID, Influenza) are allowed
What this trial measures
- Progression free survival (PFS) in patients with undetectable minimal residual disease (MRD) after 2 cycles of treatmentAt 1 year